Inogen, Inc. (INGN)

Market Cap	159.76M -20.0%
Revenue (ttm)	355.06M +2.3%
Net Income	-35.46M
EPS	-1.31
Shares Out	26.54M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	165,131
Open	6.03
Previous Close	6.03
Day's Range	5.86 - 6.21
52-Week Range	5.05 - 7.67
Beta	1.49
Analysts	Buy
Price Target	12.00 (+99.34%)
Earnings Date	Nov 5, 2026

About INGN

Inogen, Inc., a medical technology company, develops, manufactures, and markets respiratory health products in the United States and internationally. The company offers portable oxygen concentrators used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions. It provides Inogen One and Inogen Rove, an ambulatory solution for long-term oxygen therapy; Rove 4, a portable oxygen concentrator; Rove 6 concentrator; Inogen Voxi 5, a stationary oxygen concentrator; Aurora for continuous positive airw...

• Industry: Medical Devices
• Sector: Healthcare
• IPO Date: Feb 14, 2014
• Employees: 753
• Stock Exchange: Nasdaq
• Ticker Symbol: INGN
• Website: https://www.provider.inogen.com

Financial Performance

In 2025, Inogen's revenue was $348.67 million, an increase of 3.86% compared to the previous year's $335.71 million. Losses were -$22.75 million, -36.62% less than in 2024.

Analyst Summary

According to 2 analysts, the average rating for INGN stock is "Buy." The 12-month stock price target is $12.0, which is an increase of 99.34% from the latest price.

Price Target

$12.0

(99.34% upside)

Analyst Consensus: Buy

Data Sources: S&P Global Market Intelligence, CBOE, and more

Fundamental and historical data is provided by S&P Global Market Intelligence. Real-time stock price data is provided by CBOE and 15-minute delayed consolidated tape pricing data is provided by Nasdaq UTP.

Last checked:

Nov 9, 2026

Data Sources Report a data error